재생의료 시장(2026-2030년)

The global regenerative medicine market is forecasted to grow by USD 142182.8 mn during 2025-2030, accelerating at a CAGR of 26.3% during the forecast period. The report on the global regenerative medicine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of chronic diseases and target pathologies, accelerating technological advancements in stem cell research and bioengineering, escalating inflow of venture capital and strategic corporate investments.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global regenerative medicine market is segmented as below:

By Application

• Oncology
• Musculoskeletal
• Dermatology
• Others

By Technology

• Cell and tissue-based
• Gene therapy

By End-User

• Hospitals
• Clinics
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the paradigm shift toward allogeneic therapy workflows and commercial scale off-the-shelf solutions as one of the prime reasons driving the global regenerative medicine market growth during the next few years. Also, convergence of artificial intelligence and automated closed-loop manufacturing systems and evolution of strategic consolidation and specialized contract development partnerships will lead to sizable demand in the market.

The report on the global regenerative medicine market covers the following areas:

• Global regenerative medicine market sizing
• Global regenerative medicine market forecast
• Global regenerative medicine market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global regenerative medicine market vendors that include Baxter International Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Co., CRISPR Therapeutics AG, CSL Ltd., Ferring BV, Genetix Biotherapeutics Inc., Gilead Sciences Inc., Legend Biotech Corp., Medtronic Plc, Mesoblast Ltd., MiMedx Group Inc., Novartis AG, Organogenesis Holdings Inc., Sarepta Therapeutics Inc., Smith and Nephew plc, Stryker Corp., Thermo Fisher Scientific Inc., Vericel Corp., Zimmer Biomet Holdings Inc.. Also, the global regenerative medicine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Technology
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Regenerative Medicine Market 2020 - 2024
  • Historic Market Size - Data Table on Global Regenerative Medicine Market 2020 - 2024 ($ million)
• 5.2 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.3 Technology segment analysis 2020 - 2024
  • Historic Market Size - Technology Segment 2020 - 2024 ($ million)
• 5.4 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global regenerative medicine market
• 6.2 Impact of geopolitical conflicts on global regenerative medicine market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Application

• 8.1 Market segments
• 8.2 Comparison by Application
• 8.3 Oncology - Market size and forecast 2025-2030
• 8.4 Musculoskeletal - Market size and forecast 2025-2030
• 8.5 Dermatology - Market size and forecast 2025-2030
• 8.6 Others - Market size and forecast 2025-2030
• 8.7 Market opportunity by Application
  • Market opportunity by Application ($ million)

9 Market Segmentation by Technology

• 9.1 Market segments
• 9.2 Comparison by Technology
• 9.3 Cell and tissue-based - Market size and forecast 2025-2030
• 9.4 Gene therapy - Market size and forecast 2025-2030
• 9.5 Market opportunity by Technology
  • Market opportunity by Technology ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Hospitals - Market size and forecast 2025-2030
• 10.4 Clinics - Market size and forecast 2025-2030
• 10.5 Others - Market size and forecast 2025-2030
• 10.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Taiwan - Market size and forecast 2025-2030
  • 12.5.6 Singapore - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Egypt - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Chile - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Kuwait - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Rising prevalence of chronic diseases and target pathologies
  • Accelerating technological advancements in stem cell research and bioengineering
  • Escalating inflow of venture capital and strategic corporate investments
• 13.2 Market challenges
  • Exorbitant therapeutic development costs and fragile reimbursement paradigms
  • Extreme operational complexity within cellular supply chains and cold-chain logistics
  • Stringent and harmonically fragmented global regulatory oversight frameworks
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Paradigm shift toward allogeneic therapy workflows and commercial scale off-the-shelf solutions
  • Convergence of artificial intelligence and automated closed-loop manufacturing systems
  • Evolution of strategic consolidation and specialized contract development partnerships

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Baxter International Inc.
  • Baxter International Inc. - Overview
  • Baxter International Inc. - Business segments
  • Baxter International Inc. - Key offerings
  • Baxter International Inc. - Segment focus
  • SWOT
• 15.5 BioMarin Pharmaceutical Inc.
  • BioMarin Pharmaceutical Inc. - Overview
  • BioMarin Pharmaceutical Inc. - Business segments
  • BioMarin Pharmaceutical Inc. - Key offerings
  • BioMarin Pharmaceutical Inc. - Segment focus
  • SWOT
• 15.6 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.7 CSL Ltd.
  • CSL Ltd. - Overview
  • CSL Ltd. - Business segments
  • CSL Ltd. - Key offerings
  • CSL Ltd. - Segment focus
  • SWOT
• 15.8 Ferring BV
  • Ferring BV - Overview
  • Ferring BV - Product / Service
  • Ferring BV - Key offerings
  • SWOT
• 15.9 Gilead Sciences Inc.
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Business segments
  • Gilead Sciences Inc. - Key offerings
  • Gilead Sciences Inc. - Segment focus
  • SWOT
• 15.10 Legend Biotech Corp.
  • Legend Biotech Corp. - Overview
  • Legend Biotech Corp. - Product / Service
  • Legend Biotech Corp. - Key offerings
  • SWOT
• 15.11 Medtronic Plc
  • Medtronic Plc - Overview
  • Medtronic Plc - Business segments
  • Medtronic Plc - Key news
  • Medtronic Plc - Key offerings
  • Medtronic Plc - Segment focus
  • SWOT
• 15.12 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.13 Sarepta Therapeutics Inc.
  • Sarepta Therapeutics Inc. - Overview
  • Sarepta Therapeutics Inc. - Product / Service
  • Sarepta Therapeutics Inc. - Key offerings
  • SWOT
• 15.14 Smith and Nephew plc
  • Smith and Nephew plc - Overview
  • Smith and Nephew plc - Business segments
  • Smith and Nephew plc - Key offerings
  • Smith and Nephew plc - Segment focus
  • SWOT
• 15.15 Stryker Corp.
  • Stryker Corp. - Overview
  • Stryker Corp. - Business segments
  • Stryker Corp. - Key offerings
  • Stryker Corp. - Segment focus
  • SWOT
• 15.16 Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc. - Overview
  • Thermo Fisher Scientific Inc. - Business segments
  • Thermo Fisher Scientific Inc. - Key news
  • Thermo Fisher Scientific Inc. - Key offerings
  • Thermo Fisher Scientific Inc. - Segment focus
  • SWOT
• 15.17 Vericel Corp.
  • Vericel Corp. - Overview
  • Vericel Corp. - Business segments
  • Vericel Corp. - Key offerings
  • Vericel Corp. - Segment focus
  • SWOT
• 15.18 Zimmer Biomet Holdings Inc.
  • Zimmer Biomet Holdings Inc. - Overview
  • Zimmer Biomet Holdings Inc. - Business segments
  • Zimmer Biomet Holdings Inc. - Key news
  • Zimmer Biomet Holdings Inc. - Key offerings
  • Zimmer Biomet Holdings Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations